Table 2 Use of antidiabetic drugs and the risk of thyroid cancer
Drugs and No. prescriptions | Cases (%) (n = 1229) | Controls (%) (n = 7374) | Crude OR (95 % CI) | Adjusted OR (95 % CI) model 1a | Adjusted OR (95 % CI) model 2b |
|---|---|---|---|---|---|
Metformin | |||||
 No prior use | 1180 (96.0) | 7166 (97.2) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
 Any use | 49 (4.0) | 208 (2.8) | 1.46 (1.05–2.02) | 1.48 (0.86–2.54) | 1.56 (0.90–2.71) |
 1–29 | 23 (1.9) | 116 (1.6) | 1.23 (0.78–1.94) | 1.31 (0.71–2.40) | 1.34 (0.72–2.48) |
 ≥30 | 26 (2.1) | 92 (1.3) | 1.75 (1.12–2.72) | 1.83 (0.92–3.65) | 2.07 (1.03–4.18) |
Sulfonylurea | |||||
 No prior use | 1191 (96.9) | 7220 (97.9) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
 Any use | 38 (3.1) | 154 (2.1) | 1.52 (1.05–2.20) | 1.42 (0.82–2.46) | 1.41 (0.81–2.48) |
 1–29 | 19 (1.6) | 77 (1.0) | 1.51 (0.91–2.51) | 1.45 (0.76–2.77) | 1.42 (0.73–2.76) |
 ≥30 | 19 (1.6) | 77 (1.0) | 1.54 (0.91–2.59) | 1.25 (0.62–2.54) | 1.23 (0.60–2.53) |
Insulin | |||||
 No prior use | 1211 (98.5) | 7287 (98.8) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
 Any use | 18 (1.5) | 87 (1.2) | 1.25 (0.75–2.10) | 1.14 (0.62–2.09) | 1.14 (0.62–2.12) |
TZD | |||||
 No prior use | 1220 (99.3) | 7333 (99.4) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
 Any use | 9 (0.7) | 41 (0.6) | 1.32 (0.64–2.72) | 0.82 (0.36–1.84) | 0.78 (0.34–1.80) |